MyShare
Key factors
| sym | CSL |
| exch | AU |
| MCap | 134.56B |
| Beta | 0.29 |
| PE Ratio | 35.33 |
| EPS | 7.88 |
| Div | 2.48 |
| Div Yld | 1.370 |
| Div date | 2024-03-11 |
Yesterday
| sym | CSL |
| exch | AU |
| close | 273.3 |
| 50 Day MA | 281.55 |
| 200 Day MA | 270.91 |
| 52 Week High | 308.71 |
| 52 Week Low | 227.20 |
| Target Price | 303.0 |
| Market Cap Mln | 134.56K |
Share statistics
| Shares Outstanding | 483.25M |
| Shares Float | 482.67M |
| Percent Institutions | 34.89 |
| PercentInsiders | 0.498 |
Income
| Revenue TTM | 14.17B |
| Revenue Per Share TTM | 29.38 |
| Quarterly Revenue Growth YOY | 12.09 |
| Gross Profit TTM | 6.844B |
| EBITDA | 4.403B |
| Diluted Eps TTM | 7.88 |
| Quarterly Earnings Growth YOY | 16.69 |
earning
| Operating Margin TTM | 0.324 |
| Trailing PE | 35.33 |
| EPS Estimate Current Year | 9.37 |
| EPS Estimate Next Year | 10.89 |
| Earnings Share | 7.88 |
Dividend
| Forward Annual Dividend Rate | 3.81 |
| Forward Annual Dividend Yield | 1.370 |
| Payout Ratio | 46.74 |
| Dividend Date | 0000-00-00 |
| Last Split Date | 2007-10-18 |
| Last Split Factor | 3:1 |
business
| Enterprise Value Ebitda | 34.92 |
| Enterprise Value Revenue | 10.91 |
| Book Value /share | 35.55 |
| Price Book MRQ | 5.156 |
| Price Sales TTM | 9.601 |
| ProfitMargin | 0.174 |
| ReturnOnAssetsTTM | 0.064 |
| ReturnOnEquityTTM | 0.136 |
Sector
| Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry | Biotechnology |
| Gic Sector | Health Care |
| Gic Sub Industry | Biotechnology |
| Industry | Biotechnology |
| Sector | Healthcare |
Codes
| ISIN | AU000000CSL8 |
| Code | CSL |
| CountryISO | AU |
| Currency Code | AUD |
| Currency Name | Australian Dollar |
| Exchange | AU |
| Currency Symbol | A$ |
fund
| Type | Common Stock |
| UpdatedAt | 2024-04-25 |
info
| Fiscal Year End | June |
| ForwardPE | 31.34 |
| Full Time Employees | 32065 |
| International Domestic | International Domestic |
| MostRecent Quarter | 2023-12-31 |
Contact
| Name | CSL Ltd |
| Address | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 |
| Country Name | Australia |
| Phone | 61 3 9389 1911 |
| Web URL | https://www.csl.com.au |
| Logo URL | /img/logos/AU/CSL.png |
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.